[Funding alert] Switzerland-based Spiden Secures $15Million in Additional Funding

The company plans to utilize the money to complete its first phase of research and development, which has lasted six years. This phase's goals include solving the problem of fully calibration-free monitoring and paving the road for the portable product's eventual wearable downsizing.

Read also -  Netherlands-based Tidal Control Secures €500K in a Pre-Seed Round Funding

Personalized health monitoring is the focus of Spiden, a software business headed by CEO and Founder Leo Grünstein. Its methodology combines machine learning and spectroscopic methods to provide real-time, non-invasive monitoring of many biomarkers.

The goal of Spiden is to make its wearable technology commonplace, enabling early detection and prevention by giving consumers customized control over their health and lifespan. It operates out of lab facilities in Switzerland and employs over 70 people, including over 50 PhD holders and university professors.

Read also - Limburg-based Foodtech Company Verdify Raises €2.4Million in Funding

Leo Grünstein said “We aim to help customers around the world take control of their health through non-invasive access to real-time biomarker data and actionable, evidence-based insights to improve their well-being and longevity.”

About Spiden

Spiden, a dramatic improvement in human health made possible by continuous, real-time biomarker and medication monitoring. In a next-generation wearable, they want to achieve the holy grail of continuous, non-invasive, medical-grade multi-biomarker monitoring, starting with glucose and giving us the information we need to live longer, healthier lives.

Read also - Amsterdam-based Send AI Raises €2.2Million in a Pre-Seed Round Funding